PubMed Health⌕ Search

Biomedical subjects

D Caille

Publications and source records attributed to D Caille.

20 records · Page 2Linked to original sources

Single units activities in ventral posterior and posterior group thalamic nuclei during nociceptive and non nociceptive stimulations in the cat.

The purpose of this study was to define, in hyperventilated and unanesthetized cats, the role of the posterior thalamic nuclei in pain mechanisms. Unit activities of these structures were compared to those of the ventro-posterior nucleus during non-noxious (touch, brushing) and noxious stimulations (pinches and intra-arterial injections of bradykinin into the limbs). 135 cells with somatic inputs and clear peripheral excitatory receptive field were studied. The cells driven by noxious stimulations were located in the posterior group nuclei as anatomically defined by Rinvik. These units, preferentially excited from contralateral receptive fields, were localized in POm, POl, suprageniculate nuclei, the magnocellular division of the medial geniculate body (Mgmc) and the ventral part of the lateral posterior nucleus. At this level two groups of units were found: those driven only by noxious stimulations and those driven by both noxious and non-noxious stimulations. On contrast, cells recorded at the levels of the VPm and VPl were not activated by noxious stimuli. These results emphasize the role of the posterior thalamic nuclei in pain processing.

Animals↗

[Regulatory status of safety pharmacology. Implications].

Safety Pharmacology is now specified by various European and international guidelines. The ICHS7A text, which has now been implemented, requires all new compounds to be tested before any administration in humans. The compound should be evaluated under GLPs for its potential effects on so-called vital functions (cardio-vascular, respiratory and central nervous system). Also, the potential risk for QT prolongation and Torsades de Pointes should be appropriately assessed using in vitro and in vivo models (CPMP/986/96 and draft ICHS7B) before the initiation of Phase I. Various other European or international guidelines relate to more specific evaluations: abuse liability, anti-osteoporotic compounds, etc. Safety Pharmacology should also, as other studies required for regulatory submission, be conform to the electronic records and signature constraints (CFR23 part 11 for the USA) and to the format of the Common Technical Document (ICHM4). To address all these requirements, the pharmaceutical industry should now be creating specially assigned Safety Pharmacology teams.

Drug Evaluation↗